trial · primary record
Xanomeline/trospium
Schizophrenia; Psychosis
| Phase | Phase 3 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | Not stated |
| Primary completion | 2029-07-01 |
| Primary endpoint | Change in cognitive performance after 24 weeks of treatment, relative to baseline. |
| Registry ID | NCT07084831 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:46.281Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07084831
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.